Corimmun GmbH

Quick facts

Phase 2 pipeline

• COR-1 · Oncology
  COR-1 is a monoclonal antibody targeting the PD-1 receptor.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Corimmun GmbH portfolio CI brief
• Corimmun GmbH pipeline updates RSS

Related

• Sector hub: All tracked pharma companies